Home Reagents Clinical Chemistry Reagents Cannabinoids assay
Quality Guranteed Fast Delivery ad for support

Cannabinoids assay

Product Method Size Catalog Price Quantity
Cannabinoids assay Homogenous EIA R1 2 x 16.9ml, R2 2 x 8ml DA4010 $647.20
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
    _
  • Working Stability 15-25 °C
    _
  • Working Stability 2-8 °C
    28 days
Request Kit Insert

Intended Use

For the qualitative and semi-quantitative analysis of Cannabinoids (THC) in human urine. The cut-off for the qualitative application is 50ng/ml in accordance with SAMHSA recommendations. This product is suitable for use on the RX Series instruments, which includes the Rx Daytona and the Rx Imola.

This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.


Clinical Significance

The principle, active constituent in marijuana (or hashish), obtained from Cannabis Sativa plant, is the ∆1-3,4-trans tetrahydrocannabinol, frequently referred to as ∆9 tetrahydocannabinol or ∆9-THC. Cannabis has been used for its euphoric effects for over 4000 years. It is one of the most commonly used illicit drugs in the United States. Marijuana is frequently self-administered for its mood-altering properties. Chronic use has been shown to cause reversible psychological impairment, an abstinence syndrome, and can cause users to develop tolerance. At low doses, it produces mixed depressant and stimulant effects; while at higher dose it acts as a CNS depressant.

9-THC is easily absorbed by inhalation (smoking) or ingestion through the gastrointestinal tract. Due to its highly fat-soluble nature ∆9-THC is readily deposited in fatty tissues, where it may remain for days or even weeks. It is primarily metabolized in the liver to a variety of compounds, the primary one being the (11-nor ∆9-THC-9-COOH). Approximately 70% of THC is excreted in feces and urine within 72 hours of administration.


Principle


The THC immunoassay is a homogeneous enzyme immunoassay with ready-to-use liquid reagent. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity.

In the absence of drug in the sample, ∆9-THC -labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. However, when free drug is present in the sample, antibody would bind to free drug; the unbound ∆9-THC -labeled G6PDH then exhibits its maximal enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.


Available Applications

  • Various